View Older Stories View More Recent Stories

Aug 17, 2022 06:13AM H.C. Wainwright Reiterates Buy Rating, $27 Price Target on 89bio Inc. (ETNB)
Aug 16, 2022 04:39PM Clene (CLNN) New CNM-Au8 Data "Restore Opportunity" - Oppenheimer Raises PT to $17
Aug 16, 2022 07:48AM Zoom (ZM): "Significant Estimate Cuts on Increasing Churn and Competition" - Citi Downgrades to "Sell", Slashes PT
Aug 16, 2022 07:18AM "More Downside to Go" for Intel (INTC) and AMD (AMD) on PC Weakness - Citi
Aug 16, 2022 06:17AM Oppenheimer Reiterates Outperform Rating, $38 Price Target on Viridian Therapeutic (VRDN)
Aug 8, 2022 07:19AM "Shares Are Positioned to Outperform" - Avalo Therapeutics (AVTX) PT Raised to $17 at Oppenheimer
Aug 8, 2022 07:07AM "Great Scenario for KarXT" - Stifel Karuna Therapeutics (KRTX) at Buy
Aug 4, 2022 07:22AM Mirati Therapeutics (MRTX) PT Lowered to $106 at Stifel Post Earnings
Aug 4, 2022 06:33AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $92 at Oppenheimer Post Earnings
Aug 3, 2022 06:15AM "We Encourage Investors to Acquire SPNE Shares" - Cantor Fitzgerald SeaSpine (SPNE) at Overweight with $21 Price Target
Aug 3, 2022 05:59AM Evolus (EOLS) Price Decline is "Buying Opportunity" - Mizuho Securities Reiterates Stock at Buy with $15 Price Target
Aug 3, 2022 05:57AM "Outlook Moves Modestly Higher" Post Earning - Stifel Reiterates SeaSpine Holdings (SPNE) at Buy with $16 Price Target
Aug 3, 2022 05:56AM Stifel Reiterates Buy Rating, $10 Price Target on Apollo Endosurgery (APEN) Post Earnings
Aug 3, 2022 05:55AM "Yet to See True Next Leg of Growth" - BMO Capital Keeps Gilead Sciences (GILD) at Market Perform
Aug 3, 2022 05:51AM Sarepta's (SRPT) "Products Offer Significant Upside" - William Blair Reiterates Stock at Outperform
Aug 2, 2022 10:13AM Sage Therapeutics (SAGE) PT Lowered to $56 at Stifel, Reiterates "Favorable Setup"
Aug 2, 2022 08:50AM TD Group (TD) Snaps Up Cowen (COWN) for $1.3B, Further Expands US Presence
Aug 2, 2022 08:06AM Snowflake's (SNOW) Product Revenue Growth May 'Slow in Coming Quarters' - Stock Downgraded at BTIG
Aug 2, 2022 07:44AM Incyte's (INCY) "Opzelura Miss is Likely to Weigh on Shares" - BMO Capital Keeps Stock at Market Perform with $81 Price Target Post Q2 Earnings
Jul 29, 2022 10:27AM "Accelerated Approval Appears to be a Realistic Outcome" - Raymond James Reiterates Sarepta Therapeutics (SRPT) at Market Perform
Jul 29, 2022 09:21AM "RTF is Highly Unlikely, 50/50 Probability of Approval for 9001" - Cowen Reiterates Sarepta (SRPT) at Ouperform with $114 Price Target
Jul 29, 2022 06:59AM Alnylam Pharmaceuticals (ALNY) PT Lowered to $170 at Oppenheimer on Earnings Miss
Jul 28, 2022 06:14AM Oppenheimer Reiterates Perform Rating on Teva Pharma (TEVA) Post Opioid Settlement
Jul 26, 2022 08:50AM Dawson James Reiterates Buy Rating, $8.50 Price Target on 22nd Century Group (XXII) Following Equity Raise
Jul 26, 2022 07:26AM Freight Technologies (FRGT) Wins Samsung Mexico SDS Business, Shares Soar
Jul 25, 2022 04:53PM Rocket Pharmaceuticals (RCKT) PT Lowered to $56 at Stifel, Reiterates "Buy" Rating
Jul 22, 2022 08:58AM VistaGen (VTGN) Downgraded at William Blair on PALISADE-1 Failure, "Uncertainty on Path Forward for PH94B"
Jul 22, 2022 07:19AM "Tentatively Positive" into Eliem's (ELYM) ETX-810 Data - Stifel Reiterates Stock at Buy
Jul 21, 2022 10:07AM H.C. Wainwright Reiterates Buy Rating, $73 Price Target on Celldex Therapeutics (CLDX)
Jul 21, 2022 06:10AM H.C. Wainwright Reiterates Buy Rating, $35 Price Target on aTyr Pharma (LIFE)
Jul 21, 2022 05:56AM Biogen (BIIB) PT Lowered to $270 at Truist Securities on Lower Tysabri Potential and Spinraza Headwinds
Jul 21, 2022 05:54AM "See Attractive Risk-Reward" - Oppenheimer Soleno Therapeutics (SLNO) at Outperform with $3 Price Target
Jul 20, 2022 10:19AM "Continue to View Lecanemab as Risky" - Stifel Reiterates Biogen (BIIB) at Hold Following Earnings
Jul 20, 2022 07:53AM Biogen's (BIIB) "P&L Remains Challenged", Focus on CLARITY-AD - BMO Maintains Stock at Market Perform
Jul 20, 2022 05:50AM Cantor Fitzgerald Reiterates Overweight Rating, $215 Price Target on Johnson & Johnson (JNJ) Post Earnings
Jul 19, 2022 05:03PM BMO Capital Reiterates Market Perform Rating, $81 Price Target on Incyte (INCY)
Jul 19, 2022 10:03AM Full Lumryz Approval Unlikely - Avadel Pharmaceuticals (AVDL) PT Raised to $5 at Stifel on FT218 Tentative Approval but Hold Rating Maintained
Jul 19, 2022 06:11AM H.C. Wainwright Reiterates Buy Rating, $9 Price Target on Unicycive Therapeutics (UNCY)
Jul 19, 2022 05:58AM EYP-1901 Peak Sales Opportunity is Underappreciated - Cantor Fitzgerald Reiterates EyePoint (EYPT) at Overweight
Jul 19, 2022 05:55AM Stifel Reiterates Buy Rating on Ultragenyx Pharma (RARE) Following Latest GTX-102 Data
Jul 19, 2022 05:54AM Truist Securities Reiterates Buy Rating, $185 Price Target on Ultragenyx Pharma (RARE)
Jul 15, 2022 06:08AM Sanara MedTech (SMTI) PT Raised to $50 at Cantor Fitzgerald Post Accretive Scendia Acquisition, Encourage Investors to Acquire Undervalued Shares
Jul 14, 2022 12:20PM Ultragenyx's (RARE) Crysvita Royalties Sale is "Value Add, Extends Cash Runway into Profitability" - Truist Securities Bullish on Stock
Jul 14, 2022 06:37AM Theravance (TBPH) in Better Position Post Trelegy Deal, ampreloxetine Program Remains Key - Needham & Company Maintains Hold
Jul 14, 2022 06:34AM Zealand's (ZEAL) glepaglutide SBS Readout is Inflection Points for Stock - Needham & Company Reiterates Buy Rating and $32 Price Target
Jul 13, 2022 06:18PM Cantor Fitzgerald Downgrades ContraFect (CFRX) to Neutral, Lowers PT to $1 from $15
Jul 13, 2022 05:24PM Novavax's COVID Vaccine Finally Approved in the US as Cases Rise, Pfizer and Moderna Dip
Jul 13, 2022 04:11PM William Blair Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE)
Jul 13, 2022 04:09PM 9 Meter (NMTR) is "Developing Potentially Best-in-class SBS Agent" - William Blair Reiterates Outperform Rating
Jul 13, 2022 04:08PM William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
View More Recent Stories View Older Stories